Equities Analysts Set Expectations for PTGX Q1 Earnings

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Equities research analysts at Wedbush raised their Q1 2025 earnings estimates for shares of Protagonist Therapeutics in a note issued to investors on Tuesday, November 19th. Wedbush analyst Y. Zhong now expects that the company will post earnings of $1.92 per share for the quarter, up from their previous forecast of ($0.64). Wedbush currently has a “Outperform” rating and a $58.00 target price on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.28 per share. Wedbush also issued estimates for Protagonist Therapeutics’ FY2025 earnings at ($0.16) EPS.

A number of other equities analysts have also recently weighed in on the stock. Truist Financial initiated coverage on shares of Protagonist Therapeutics in a research report on Monday, September 9th. They set a “buy” rating and a $60.00 price target on the stock. JMP Securities decreased their price objective on Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating for the company in a report on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Protagonist Therapeutics in a research report on Tuesday. TD Cowen raised Protagonist Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 25th. Finally, StockNews.com raised Protagonist Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $53.57.

Protagonist Therapeutics Stock Performance

Shares of PTGX stock opened at $46.46 on Thursday. Protagonist Therapeutics has a 52-week low of $16.80 and a 52-week high of $48.89. The stock has a market cap of $2.77 billion, a PE ratio of 17.82 and a beta of 2.17. The firm’s 50 day moving average price is $45.26 and its two-hundred day moving average price is $39.02.

Insider Activity at Protagonist Therapeutics

In related news, Director William D. Waddill sold 8,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total transaction of $360,000.00. Following the sale, the director now owns 12,000 shares in the company, valued at approximately $540,000. This trade represents a 40.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Arturo Md Molina sold 1,906 shares of the company’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $40.98, for a total value of $78,107.88. Following the sale, the insider now owns 46,444 shares of the company’s stock, valued at $1,903,275.12. The trade was a 3.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 24,109 shares of company stock worth $1,069,999. Company insiders own 5.40% of the company’s stock.

Institutional Trading of Protagonist Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC boosted its position in shares of Protagonist Therapeutics by 749.2% during the 3rd quarter. GAMMA Investing LLC now owns 552 shares of the company’s stock worth $25,000 after purchasing an additional 487 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in Protagonist Therapeutics during the 1st quarter worth $35,000. Exchange Traded Concepts LLC bought a new stake in shares of Protagonist Therapeutics in the 3rd quarter worth $43,000. CWM LLC raised its holdings in shares of Protagonist Therapeutics by 910.3% in the third quarter. CWM LLC now owns 1,273 shares of the company’s stock valued at $57,000 after purchasing an additional 1,147 shares during the last quarter. Finally, Lazard Asset Management LLC purchased a new position in shares of Protagonist Therapeutics in the 1st quarter worth approximately $69,000. 98.63% of the stock is currently owned by institutional investors and hedge funds.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.